What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur
Portfolio Pulse from Vandana Singh
FDA's Gastrointestinal Drugs Advisory Committee voted against the benefits of Intercept Pharmaceutical's Ocaliva 25 mg for NASH patients with stage 2 or 3 fibrosis. HC Wainwright downgraded the stock to Sell from Neutral, citing potential commercial failure and competition from other drugs.
May 22, 2023 | 8:20 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Intercept Pharmaceutical's Ocaliva faces FDA rejection for NASH patients, leading to a downgrade to Sell by HC Wainwright.
The FDA committee's negative vote on Ocaliva's benefits for NASH patients with stage 2 or 3 fibrosis directly impacts Intercept Pharmaceutical. HC Wainwright's downgrade to Sell from Neutral further indicates a negative outlook for the company's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100